Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Clinical trial NCT05660967 · TERMINATED
Trial details
- NCT number
- NCT05660967
- Sponsor
- Genmab
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-06
- Primary completion
- 2026-06-10
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.